MA54940A - Dérivés d'acides aminés pour le traitement de maladies inflammatoires - Google Patents

Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Info

Publication number
MA54940A
MA54940A MA054940A MA54940A MA54940A MA 54940 A MA54940 A MA 54940A MA 054940 A MA054940 A MA 054940A MA 54940 A MA54940 A MA 54940A MA 54940 A MA54940 A MA 54940A
Authority
MA
Morocco
Prior art keywords
treatment
amino acid
acid derivatives
inflammatory diseases
inflammatory
Prior art date
Application number
MA054940A
Other languages
English (en)
Other versions
MA54940B1 (fr
Inventor
Chao Jin
Michael Mullan
Daniel Paris
Original Assignee
The Roskamp Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Roskamp Inst filed Critical The Roskamp Inst
Publication of MA54940A publication Critical patent/MA54940A/fr
Publication of MA54940B1 publication Critical patent/MA54940B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA54940A 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires MA54940B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962795549P 2019-01-22 2019-01-22
US201962871951P 2019-07-09 2019-07-09
PCT/US2020/014636 WO2020154420A2 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires
EP20708296.7A EP3924349B1 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Publications (2)

Publication Number Publication Date
MA54940A true MA54940A (fr) 2021-12-22
MA54940B1 MA54940B1 (fr) 2025-09-30

Family

ID=69726748

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54940A MA54940B1 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Country Status (30)

Country Link
US (1) US20220081415A1 (fr)
EP (1) EP3924349B1 (fr)
JP (2) JP7784708B2 (fr)
KR (1) KR20210141930A (fr)
CN (1) CN113614074A (fr)
AU (2) AU2020211980B2 (fr)
BR (1) BR112021014372A2 (fr)
CA (1) CA3127246A1 (fr)
CL (1) CL2021001944A1 (fr)
CO (1) CO2021010931A2 (fr)
DK (1) DK3924349T3 (fr)
EC (1) ECSP21062210A (fr)
ES (1) ES3038582T3 (fr)
FI (1) FI3924349T3 (fr)
HR (1) HRP20251058T1 (fr)
HU (1) HUE072722T2 (fr)
IL (1) IL284980A (fr)
LT (1) LT3924349T (fr)
MA (1) MA54940B1 (fr)
MD (1) MD3924349T2 (fr)
MX (1) MX2021008748A (fr)
PH (1) PH12021551760A1 (fr)
PL (1) PL3924349T3 (fr)
PT (1) PT3924349T (fr)
RS (1) RS67095B1 (fr)
SG (1) SG11202107977TA (fr)
SI (1) SI3924349T1 (fr)
SM (1) SMT202500289T1 (fr)
WO (1) WO2020154420A2 (fr)
ZA (1) ZA202105229B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113209A1 (fr) 2018-11-30 2020-06-04 Comet Therapeutics, Inc. Dérivés de pantéthéine et leurs utilisations
WO2025144874A1 (fr) 2023-12-24 2025-07-03 The Roskamp Institute Inhibiteurs puissants de nf-kb destinés au traitement de maladies inflammatoires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1999011657A1 (fr) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Derives de 1-amino-7-isoquinoline comme inhibiteurs de serine protease
US6218390B1 (en) * 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
US8143259B2 (en) * 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
US20120046357A1 (en) * 2009-05-01 2012-02-23 Profectus Biosciences, Inc. Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB)

Also Published As

Publication number Publication date
WO2020154420A4 (fr) 2020-11-12
SG11202107977TA (en) 2021-08-30
CN113614074A (zh) 2021-11-05
CA3127246A1 (fr) 2020-07-30
SMT202500289T1 (it) 2025-11-10
CO2021010931A2 (es) 2022-01-17
AU2025283544A1 (en) 2026-01-15
FI3924349T3 (fi) 2025-08-29
LT3924349T (lt) 2025-10-10
BR112021014372A2 (pt) 2021-09-28
MX2021008748A (es) 2022-01-24
ECSP21062210A (es) 2022-06-30
RS67095B1 (sr) 2025-09-30
MA54940B1 (fr) 2025-09-30
SI3924349T1 (sl) 2025-10-30
JP2025062004A (ja) 2025-04-11
ES3038582T3 (en) 2025-10-14
EP3924349B1 (fr) 2025-06-25
EP3924349A2 (fr) 2021-12-22
US20220081415A1 (en) 2022-03-17
MD3924349T2 (ro) 2025-11-30
AU2020211980B2 (en) 2025-09-18
KR20210141930A (ko) 2021-11-23
ZA202105229B (en) 2022-12-21
DK3924349T3 (da) 2025-09-08
WO2020154420A3 (fr) 2020-09-10
JP2022524571A (ja) 2022-05-09
HRP20251058T1 (hr) 2025-11-07
IL284980A (en) 2021-09-30
AU2020211980A1 (en) 2021-08-19
WO2020154420A2 (fr) 2020-07-30
HUE072722T2 (hu) 2025-12-28
JP7784708B2 (ja) 2025-12-12
CL2021001944A1 (es) 2022-05-06
PT3924349T (pt) 2025-10-01
PH12021551760A1 (en) 2022-05-30
PL3924349T3 (pl) 2025-09-22

Similar Documents

Publication Publication Date Title
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA55604A (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP4045036A4 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
EP3861131A4 (fr) Thérapie génique pour le traitement de l'acidémie propionique
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP4073060A4 (fr) Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
MA54940A (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
MA55141A (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP3766503A4 (fr) Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires
EP4045506A4 (fr) Dérivés de 4-(imidazo[1,2-a] pyridin-3-yl)-n-(pyridin-3-yl)pyrimidin-2-amine pour le traitement de maladies et d'affections prolifératives